Zymeworks (NASDAQ:ZYME) said it has achieved a $14M cash research milestone through its collaboration with GSK (GSK). Under ...

Zymeworks (ZYME) announced achievement of a $14M cash research milestone from GSK (GSK) associated with a clinical milestone. “In April 2016, ...

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of ...

Zymeworks Inc. (NYSE:ZYME – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven research firms ...

Zymeworks Inc. (ZYME) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...

VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology ...

Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Zymeworks in a note issued to ...

Zymeworks (NYSE:ZYME) came into focus in late December when major shareholder EcoR1 Capital increased its stake. Already a 10% holder and board member, EcoR1 made several purchases in December and ...

Zymeworks (ZYME) appointed Oleg Nodelman to its board of directors, effective February 17. Nodelman is the Founder and Managing Director of ...